Magdalena Kegel,  —

Dr. Beth A. Smith with the University at Buffalo has received a mental healthcare award from the Cystic Fibrosis Foundation for her work in advancing the understanding and care of mental health in cystic fibrosis — regarding both the prevalence of depression among patients and its impact on…

Galapagos is advancing its development of a range of cystic fibrosis (CF) treatments intended for use in combinations — either with already approved CF therapies or with its own compounds — the Belgian biotech company announced. Phase 2 trials Among the advances is completion of a Phase 2 trial…

Mothers of young children with cystic fibrosis bear a heavier caregiving load than fathers, according to an Irish study. The research also showed that the caregiving burden increased as children grew older and when they became infected with the bacteria Pseudomonas aeruginosa. Although University College Dublin researchers identified circumstances that could affect…

Kalydeco (ivacaftor) is safe and effective in 1- and 2-year-olds with cystic fibrosis (CF), Vertex Pharmaceuticals reported based on data from its ongoing Phase 3 clinical trial in infants and toddlers. The treatment’s safety was similar to that seen in studies of older children, the company said. Moreover,…

Adding  investigational CFTR corrector GLPG2222 safely improved disease parameters in cystic fibrosis (CF) patients treated with Kalydeco (ivacaftor), reported the therapy’s Belgian developer, Galapagos, citing Phase 2 clinical trial data. The benefit of adding GLPG2222 was similar to that seen in an earlier study of a tezacaftor-Kalydeco combination, researchers said.

Spyryx Biosciences recently presented preclinical data supporting the clinical benefits of its cystic fibrosis (CF) treatment candidate SPX-101, intended to improve lung function in all patients regardless of their underlying disease-causing mutation. The data, presented in four posters at the recent North American Cystic Fibrosis Conference (NACFC) in Indianapolis,…

Experiments in live pigs show that the genetic mutation that causes cystic fibrosis (CF) prevents secretion of airway surface liquid when bacteria enter the lungs — a mechanism that may, at least in part, explain why CF patients are not able to ward off bacterial infections. Researchers at the…

Researchers have identified a signal that controls when lung bacteria in cystic fibrosis patients start producing biofilm — a sticky secretion that protects them from attack and makes the bacteria virtually impossible to get rid of. Since the signal suppresses bacteria’s biofilm-making machinery, the finding could lead to treatments that…

Researchers have discovered that the Bpifb1 gene plays an important role in controlling levels of a mucin protein called MUC5B, one of the main components of mucus. This means that the gene also plays a crucial role in protecting the body’s airways. The team found that deleting the Bpifb1 gene in…

Women with diabetes associated with cystic fibrosis (CF) do not risk their disease worsening by becoming pregnant. Their children also are not affected by the presence of diabetes, according to a study by researchers at the University of Lyon in France. The only significant difference the study found between…